Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

HER2 positive cancers more likely to respond to treatment that specifically attacks the HER2 protein. Alternatively, if you have lower amounts of the HER2 protein, your cancer is HER2 negative.

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Accepted for Priority Review Zongertinib (Boehringer Ingelheim) Tyrosine kinase inhibitor that selectively blocks HER2 Treatment of adult patients with unresectable or metastatic non-small cell ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...